Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

This study is currently recruiting participants.

Verified by Ludwig-Maximilians - University of Munich, November 2006

Sponsored by:	Ludwig-Maximilians - University of Munich
Information provided by:	Ludwig-Maximilians - University of Munich
ClinicalTrials.gov Identifier:	NCT00406900

Purpose

Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker "Melanoma inhibitory activity" is a promising marker. Study hypothesis is to detect metastatic lesions in an early stage. This would increase life expectance of our patients

Condition	Intervention
Melanoma Radiotherapy Metastatic Disease	Procedure: Treatment of metastatic disease

MedlinePlus related topics: Cancer Melanoma Radiation Therapy

U.S. FDA Resources

Study Type:	Observational
Study Design:	Screening, Longitudinal, Defined Population, Prospective Study

Further study details as provided by Ludwig-Maximilians - University of Munich:

Estimated Enrollment:	560
Study Start Date:	January 1999
Estimated Study Completion Date:	September 2006

Detailed Description:

Serum is taken from each melanoma patient at every follow up after signed concent. With ELISA the marker MIA is evaluated. An increase of MIA serum level will lead to search for metastasis by oncologists.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

uveal melanoma (With/without overt metastatic disease)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00406900

Contacts

Contact: Ulrich C Schaller, MD

+49/89/5160 ext 3811

ulrich.schaller@med.uni-muenchen.de

Locations

Germany
Dept of Ophthalmology, University of Munich	Recruiting
Munich, Germany, 80538
Contact: Ulrich C Schaller, MD +49895160 ext 3811 ulrich.schaller@med.uni-muenchen.de
Principal Investigator: Ulrich C Schaller, MD

Sponsors and Collaborators

Ludwig-Maximilians - University of Munich

Investigators

Principal Investigator:

Ulrich C Schaller, MD

University of Munich, Germany

More Information

Publications of Results:

Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res. 2002 Dec;12(6):593-9.

Study ID Numbers:	MIA
Study First Received:	November 29, 2006
Last Updated:	December 5, 2006
ClinicalTrials.gov Identifier:	NCT00406900
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Ludwig-Maximilians - University of Munich:

uveal melanoma
metastatic disease

Study placed in the following topic categories:

Neuroectodermal Tumors
Uveal melanoma
Intraocular melanoma
Nevus, Pigmented
Neoplasms, Germ Cell and Embryonal

Neoplasm Metastasis
Neuroepithelioma
Nevus
Neuroendocrine Tumors
Melanoma

Additional relevant MeSH terms:

Neoplastic Processes
Neoplasms
Pathologic Processes

Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on February 12, 2009